B. J. KENNEDY, MD., F.A.C.P.; ATHANASIOS THEOLOGIDES, M.D., PH.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
The combination of several drug agents for the treatment of malignant diseases represents a new era in the chemotherapy of cancer and emphasizes that cure of some neoplastic diseases is a potentially attainable goal. In Hodgkin's disease, lymphoma, acute leukemia, and breast cancer, combination drug therapy has made possible a higher rate of regression (tumor shrinkage) and, more important, a higher rate of complete remission (disappearance of measurable tumor). As a result, combination chemotherapy is being endorsed by clinicians. This mode of therapy has been accepted, however, for many malignant neoplasms without adequately controlled studies.
Historically, the first phase of
KENNEDY BJ, THEOLOGIDES A. Controls in Cancer Chemotherapy. Ann Intern Med. ;76:321–322. doi: 10.7326/0003-4819-76-2-321
Download citation file:
Published: Ann Intern Med. 1972;76(2):321-322.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use